Skip to content
Screener

Monopar Therapeutics MNPR Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$100M+31.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
Wave Life Sciences logo
Wave Life SciencesWVE
$330K-97.2%
Prime Medicine logo
Prime MedicinePRME
$361K+83.2%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$798.6M+307%
Enterprise value$746.28M+378%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 2:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-016982
Line itemFor the Three Months Ended / March 31, 2026For the Three Months Ended / March 31, 2025
Cash flows from financing activities:
Taxes paid related to net share settlement of vested restricted stock units(200,203)(131,129)
Cash proceeds from the issuance of stock upon exercise of stock options15,447
Net cash provided by (used in) financing activities(200,203)(115,682)
Effect of exchange rate and valuation changes on cash equivalents(31,628)(54)
Net increase (decrease) in cash and cash equivalents(9,289,289)(6,104,880)
Cash and cash equivalents at beginning of period61,833,55245,816,289
Cash and cash equivalents at end of period$52,544,263$39,711,409

Document

FAQ

What is Monopar Therapeutics's financing cash flow?
Monopar Therapeutics (MNPR) reported financing cash flow of -$200.2K in Q1 2026.
How has Monopar Therapeutics's financing cash flow changed year-over-year?
Monopar Therapeutics's financing cash flow decreased by 73.1% year-over-year, from -$115.68K to -$200.2K.
What is the long-term trend for Monopar Therapeutics's financing cash flow?
Over 2 years (2022 to 2025), Monopar Therapeutics's financing cash flow has grown at a 5189.0% compound annual growth rate (CAGR), from $32.87K to $91.96M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Monopar Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude